Form 4: CRL Executive Sells Shares Under 10b5-1 Plan

Charles River Laboratories EVP Joseph W. LaPlume sold 400 shares of common stock for $163.72 per share, a transaction executed under a Rule 10b5-1 plan.

Summary

• Joseph W. LaPlume, Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International, Inc. (CRL), sold 400 shares of the company's common stock.
• The transaction occurred on August 22, 2025, with the shares sold at a price of $163.72 per share.
• This sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for buying or selling company stock.
• Following this transaction, Mr. LaPlume directly beneficially owns 23,716 shares of CRL common stock.
• The Form 4 filing, reporting this transaction, was signed on January 19, 2026, approximately five months after the transaction date.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can be seen as slightly negative, the small amount and the fact it's under a 10b5-1 plan mitigate strong negative sentiment. The significant delay in filing is a procedural concern, but the transaction itself is routine.

Negatives

• An executive sale of company stock, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership.
• The Form 4 filing occurred approximately five months after the transaction date, which is a significant delay compared to the typical two-business-day requirement for Form 4 filings.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing reports a routine insider stock transaction and does not provide information relevant to broader industry trends or the competitive landscape of the pharmaceutical and biotechnology services industry.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, though the amount is small relative to total shares outstanding and the executive's remaining holdings. The delayed filing could raise questions about compliance procedures.

Key Dates

Keywords

Charles River Laboratories, CRL, Insider Trading, Form 4, Joseph W. LaPlume, Stock Sale, 10b5-1 Plan, Executive Compensation